What patents cover Sogroya (somapacitan), and what are they protecting?
Sogroya is the brand name for somapacitan, a long-acting human growth hormone (hGH) analog developed to treat growth hormone deficiency. The company’s patent protection for a product like this typically covers things such as the molecule and its specific use, along with formulation and dosing regimens designed to achieve prolonged exposure. The exact patent numbers, assignees, and claim scopes are country- and patent-family-specific.
To answer precisely, I need at least one of the following: the country/region you care about (for example, US, EP, UK, JP, or AU) or a patent/application number you’ve seen referenced.
When does Sogroya’s patent protection expire?
Patent expiry depends on:
- the filing dates in each jurisdiction
- whether patents have been granted and when
- any patent term adjustments, extensions, or regulatory exclusivity periods tied to the approval date in that country
If you tell me the country (e.g., US vs EU), I can map the likely “earliest possible” expiry timing versus later events like added protection (if any) from regulatory exclusivity.
Are there patents still in force, or is a generic/biosimilar possible soon?
For biologics like somapacitan, challengers generally look at:
- whether there is still active patent coverage on the specific claims being infringed (often device/formulation/dosing or method-of-treatment claims)
- whether the biologic is considered sufficiently similar for biosimilar pathways
- whether litigation results in an injunction or delayed approval
Whether a biosimilar could launch “soon” hinges on both patent status and local regulatory pathways in the target market.
Why do Sogroya patent disputes matter for patients and pricing?
If patents are still active, they usually limit the number of competing products that can enter the market through formal approval routes. Once key protections expire (or are overturned), additional products can enter, which can affect:
- availability
- uptake and competition
- pricing and reimbursement dynamics
What I need from you to give a concrete patent answer
Please reply with one detail so I can be specific:
1) which country/region you mean by “Sogroya patent” (US, EU, UK, etc.), and/or
2) any patent number you’ve already found (or the company name you suspect is the assignee), and/or
3) whether you mean “the main patent for somapacitan” or “latest litigation/patent challenges.”
Sources: None provided in the prompt.